

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Keymed Biosciences Inc.**  
**康諾亞生物醫藥科技有限公司**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2162)**

**VOLUNTARY ANNOUNCEMENT  
SHARE PURCHASE PURSUANT TO  
THE 2022 RESTRICTED SHARE UNIT SCHEME**

This announcement is made by Keymed Biosciences Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

References are made to the announcements of the Company dated January 21, 2022 and January 28, 2022 (the “**Announcement(s)**”) in relation to the adoption of the 2022 restricted share unit scheme of the Company (the “**Scheme**”). Unless otherwise specified, capitalized terms used herein shall have the meaning as those defined in the Announcements.

The Board wishes to announce that since January 2, 2024 and up to the date of this announcement, the Trustee has purchased a total number of 765,500 Shares on the market at prices in the range of HK\$31.25 to HK\$46.60 per Share pursuant to the rules of the Scheme. As of the date of this announcement, the Trustee has purchased an aggregate of 3,897,000 Shares for the purpose of the Scheme, representing approximately 1.39% of the total number of Shares in issue. The Shares so purchased will be used as Awards for the eligible Participants under the Scheme to incentivize them to make contribution to the Group.

The Company may instruct the Trustee to make further purchases pursuant to the Scheme. The Company will comply with the Listing Rules and the rules of the Scheme in granting Awards pursuant to the Scheme in the future.

By order of the Board  
**Keymed Biosciences Inc.**  
**Dr. Bo CHEN**  
*Chairman*

Hong Kong, January 22, 2024

*As at the date of this announcement, the Board of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive directors; Mr. Qi CHEN, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive directors; and Prof. Xiao-Fan WANG, Prof. Yang KE and Mr. Cheuk Kin Stephen LAW as independent non-executive directors.*